Related Experiment Videos
[The analysis of leukemic relapse after allogeneic bone marrow transplantation]
M Yoshimura1, H Yoshida, T Matsunashi
1Center for Adult Disease, Osaka.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology
|November 1, 1991
Summary
Leukemic relapse remains a significant cause of death following allogeneic bone marrow transplantation (BMT). This study analyzes relapse rates and survival outcomes in 52 patients, highlighting the impact of leukemia type and graft-versus-host disease (GVHD).
Area of Science:
- Hematology
- Oncology
- Transplantation Immunology
Context:
- Allogeneic bone marrow transplantation (BMT) is a critical treatment for various hematologic malignancies.
- Leukemic relapse is a primary cause of treatment failure and mortality post-BMT.
- Understanding factors influencing relapse is crucial for improving patient outcomes.
Purpose:
- To analyze the incidence and patterns of leukemic relapse in patients undergoing allogeneic BMT.
- To evaluate the impact of specific leukemia types (CML, ANLL, ALL) on relapse rates and disease-free survival (DFS).
- To assess the influence of graft-versus-host disease (GVHD) on DFS after BMT.
Summary:
- This study analyzed 52 patients receiving allogeneic BMT with TBI + CY conditioning and cyclosporine-A/methotrexate prophylaxis.
- Relapse ratios varied by leukemia type: CML (13%), ANLL (18%), and ALL (25%). Three-year DFS was 68% for CML, 72% for ANLL, and 49% for ALL.
- DFS was influenced by GVHD severity, with higher DFS observed in patients with Grade I acute GVHD and no chronic GVHD.
Impact:
- Leukemic relapse is identified as the major cause of death post-BMT in this cohort.
- The findings underscore the need for strategies to mitigate relapse risk and manage GVHD effectively.
- Understanding relapse dynamics and GVHD impact can inform future BMT protocols and patient management.